Literature DB >> 24126807

Vascularized composite allografts and solid organ transplants: similarities and differences.

Annemarie Weissenbacher1, Theresa Hautz, Johann Pratschke, Stefan Schneeberger.   

Abstract

PURPOSE OF REVIEW: Vascularized composite allotransplantation (VCA) is a treatment for complex tissue injuries and defects of extremities and face. During the past thirteen years, more than 100 VCA cases have been reported. Form and function restored with VCA have exceeded the results achieved with conventional surgical techniques. The review summarized the development in VCA over the past 12 months with references of and comparison with solid organ transplantation. RECENT
FINDINGS: The highlights reported in the latest publications included a better understanding of topical immunosuppressants for prevention and treatment of VCA rejection, mechanisms of chronic rejection and minimization of immunosuppressive maintenance treatment using a cell-based protocol in human upper-extremity transplantation.
SUMMARY: We herein summarize the progress made in VCA in the last year with a focus on new clinical immunosuppressive strategies and novel targets for immunosuppression and immunomodulation including the application of mesenchymal stem cells for transplant tolerance.

Entities:  

Mesh:

Year:  2013        PMID: 24126807     DOI: 10.1097/MOT.0000000000000019

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  4 in total

Review 1.  Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.

Authors:  Maximilian Kueckelhaus; Sebastian Fischer; Midas Seyda; Ericka M Bueno; Mario A Aycart; Muayyad Alhefzi; Abdallah ElKhal; Bohdan Pomahac; Stefan G Tullius
Journal:  Transpl Int       Date:  2015-09-14       Impact factor: 3.782

Review 2.  Vascularized Composite Allografts: Procurement, Allocation, and Implementation.

Authors:  Axel Rahmel
Journal:  Curr Transplant Rep       Date:  2014

3.  The Macrophage-depleting Agent Clodronate Promotes Durable Hematopoietic Chimerism and Donor-specific Skin Allograft Tolerance in Mice.

Authors:  Zhanzhuo Li; Xin Xu; Xingmin Feng; Philip M Murphy
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

4.  Characteristics and Immunomodulating Functions of Adipose-Derived and Bone Marrow-Derived Mesenchymal Stem Cells Across Defined Human Leukocyte Antigen Barriers.

Authors:  Matthias Waldner; Wensheng Zhang; Isaac B James; Kassandra Allbright; Emmanuelle Havis; Jacqueline M Bliley; Aurora Almadori; Riccardo Schweizer; Jan A Plock; Kia M Washington; Vijay S Gorantla; Mario G Solari; Kacey G Marra; J Peter Rubin
Journal:  Front Immunol       Date:  2018-07-24       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.